Search Result

Results for "

dgk

" in MedChemExpress (MCE) Product Catalog:

By Targets:	DGK (44) 5-HT Receptor (4) Akt (1) AMPK (1) Anaplastic lymphoma kinase (ALK) (1) Apoptosis (3) Autophagy (1) Biochemical Assay Reagents (1) c-Met/HGFR (1) Caspase (2) Drug Derivative (1) Endogenous Metabolite (1) ERK (4) Fluorescent Dye (1) HIV (1) IFNAR (3) Interleukin Related (12) Isotope-Labeled Compounds (1) Keap1-Nrf2 (1) Mitochondrial Metabolism (1) Molecular Glues (1) mTOR (1) NF-κB (1) NO Synthase (1) Oxidative Phosphorylation (1) PERK (1) PI3K (1) PKC (6) Reactive Oxygen Species (ROS) (1) Reference Standards (4) Small Interfering RNA (siRNA) (5) Src (1) STAT (1)
By Research Areas:	Cancer (41) Cardiovascular Disease (3) Infection (3) Inflammation/Immunology (16) Metabolic Disease (2)
Oligonucleotides:	Mouse Pre-designed siRNA Sets (2) Human Pre-designed siRNA Sets (3) siRNAs (5)

Inhibitors & Agonists

Fluorescent Dye

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Oligonucleotides

Targets Recommended: DGK

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-159649

BMS-986408	DGK PERK Interleukin Related	Inflammation/Immunology Cancer
BMS-986408 is an orally active inhibitor of DGKα and DGKζ, with IC₅₀ values of 0.0003 μM and 0.002 μM, respectively. BMS-986408 activates intratumoral T cell responses, enhances the priming and expansion of tumor-reactive T cells in tumor-draining lymph nodes, and functions as an immunostimulant. BMS-986408 can be used in the research of tumors .

HY-108355

R59949 1 Publications Verification	PKC	Cancer
R59949 is a pan diacylglycerol kinase (DGK) inhibitor with an IC₅₀ of 300 nM. R59949 strongly inhibits the activity of type I DGK α and γ and moderately attenuates the activity of type II DGK θ and κ. R59949 activates protein kinase C (PKC) by enhancing the levels of the endogenous ligand diacyl glycerol .

HY-153343

Veludacigib 3 Publications Verification BAY 2965501	DGK	Cancer
BAY 2965501 is a potent and selective diacylglycerol kinase zeta (DGKζ) inhibitor. BAY 2965501 induces pERK activation. BAY 2965501 can be used for the research of cancer .

HY-107613

R 59-022 2 Publications Verification DKGI-I; Diacylglycerol kinase inhibitor I	PKC 5-HT Receptor	Inflammation/Immunology
R 59-022 (DKGI-I) is a *DGK* inhibitor (IC₅₀: 2.8 µM). R 59-022 inhibits the phosphorylation of OAG to OAPA. R 59-022 is a 5-HT Receptor antagonist, and activates protein kinase C (PKC). R 59-022 potentiates thrombin-induced diacylglycerol production in platelets and inhibits phosphatidic acid production in neutrophils .

HY-N0097A

9-β-D-Arabinofuranosylguanine AraG	Drug Derivative	Cancer
9-β-D-Arabinofuranosylguanine is a Guanosine (HY-N0097) analog and shows high affinity for deoxyguanosine kinase (dGK) with a K_m of 8.0 μM. 9-β-D-Arabinofuranosylguanine can be used for the research of T-cell lymphoblastic disease .

HY-149874

BMS-502 1 Publications Verification	DGK	Inflammation/Immunology Cancer
BMS-502 (Compound 22) is a potent dual inhibitor of diacylglycerol kinase (DGK) α and ζ with IC₅₀ of 4.6 nM and 2.1 nM. BMS-502 enhanced T cell immune responses in mice. BMS-502 can be used in tumor immunity related research .

HY-153793

Alcudacigib dgkζ-IN-1	DGK IFNAR Interleukin Related ERK	Cancer
Alcudacigib (ASP1570; DGKζ-IN-1) is an orally active diacylglycerol kinase ζ (DGKζ) inhibitor, with an IC₅₀ of 4.7 nM against human DGKζ and an IC₅₀ of 3.0 nM against mouse DGKζ. Alcudacigib selectively inhibits the kinase activity of DGKζ and induces proteasome-dependent degradation of DGKζ protein. Alcudacigib enhances the anti-tumor functions of T cells and NK cells. Alcudacigib can be used for the research of advanced/metastatic solid tumors .

HY-121638A

(5Z,2E)-CU-3 1 Publications Verification	DGK Apoptosis Interleukin Related Caspase	Cancer
(5Z,2E)-CU-3 is an isomer of CU-3 (HY-121638). CU-3 is a DGKα inhibitor with an IC₅₀ of 0.6 μM. CU-3 competitively reduces DGKα’s affinity for ATP via binding to the enzyme’s catalytic region. CU-3 induces apoptosis in cancer cells. CU-3 promotes T-cell activation and enhances IL-2 production. CU-3 can be used for the research of hepatocellular carcinoma and cervical cancer .

HY-135898

DGK-IN-1	DGK	Inflammation/Immunology Cancer
DGK-IN-1 is a *DGK* inhibitor (DGKa/DGKz IC₅₀: 0.65/0.25 μM). DGK-IN-1 is a T cell activator that can be used in cancer and viral infection research .

HY-100960

Dioctanoylglycol Ethylene glycol dicaprylate; Ethylene glycol dioctanoate; Ethylenedioctanoate	DGK	Cardiovascular Disease
Dioctanoylglycol (Ethylene glycol dicaprylate), a diacylglycerol analog, is a diacylglycerol kinase (DGK) inhibitor (K_i of 58 μM) .

HY-149665

BMS-684 1 Publications Verification	DGK	Cancer
BMS-684 is a selective DGKα inhibitor with an IC₅₀ of 15 nM. BMS-684 inhibits DGKα kinase activity with >100-fold selectivity over the related DGK type I family members DGKβ and DGKγ. BMS-684 does not inhibit any of the other seven DGK isozymes .

HY-153343A

(S)-Veludacigib (S)-BAY 2965501	DGK ERK	Cancer
(S)-BAY 2965501 is the left-handed isomer of BAY 2965501 (HY-153343). BAY 2965501 is a potent and selective diacylglycerol kinase zeta (DGKζ) inhibitor. BAY 2965501 induces pERK activation. BAY 2965501 can be used for the research of cancer .

HY-153793A

Alcudacigib TFA dgkζ-IN-1 TFA	DGK IFNAR Interleukin Related ERK	Cancer
Alcudacigib (ASP1570; DGKζ-IN-1) TFA is an orally active diacylglycerol kinase ζ (DGKζ) inhibitor, with an IC₅₀ of 4.7 nM against human DGKζ and an IC₅₀ of 3.0 nM against mouse DGKζ. Alcudacigib TFA selectively inhibits the kinase activity of DGKζ and induces proteasome-dependent degradation of DGKζ protein. Alcudacigib TFA enhances the anti-tumor functions of T cells and NK cells. Alcudacigib TFA can be used for the research of advanced/metastatic solid tumors .

HY-171051

Pasodacigib	DGK	Others
DGKα-IN-9 (example 298) is an inhibitor of DGKα .

HY-156569

DGKα-IN-2	DGK Anaplastic lymphoma kinase (ALK)	Inflammation/Immunology Cancer
DGKα-IN-2 (example 48) is a DGKα inhibitor with the IC₅₀ of 0.9 nM, extracted from patent WO2021105115. DGKα-IN-2 significantly enhances the anti-tumor effect of anti-PD-1 by increasing the proliferation and function of T cells. DGKα-IN-2 has the potential for cancer and immunology study.

HY-149667

BMS-332	DGK	Cancer
BMS-332 is a dual DGKα/ζ lipid kinase inhibitor, with IC₅₀s of 5 and 1 nM against DGKα and DGKζ, respectively. BMS-332 enhances the antigen-specific T cell response. BMS-332 reduces the viral load in the liver and spleen when combined with anti-PD-1 in chronic infection models. BMS-332 can be used for the study of T cell immune checkpoint strategy .

HY-107613A

R 59-022 hydrochloride 2 Publications Verification DKGI-I hydrochloride; Diacylglycerol kinase inhibitor I hydrochloride	PKC 5-HT Receptor	Infection Inflammation/Immunology Cancer
R 59-022 (DKGI-I) hydrochloride is a *DGK* inhibitor (IC₅₀: 2.8 µM). R 59-022 hydrochloride inhibits the phosphorylation of OAG to OAPA. R 59-022 hydrochloride is a 5-HT Receptor antagonist, and activates protein kinase C (PKC). R 59-022 hydrochloride potentiates thrombin-induced diacylglycerol production in platelets and inhibits phosphatidic acid production in neutrophils .

HY-177603

DGK-IN-13	DGK	Cancer
DGK-IN-13 is a *DGK* inhibitor. DGK-IN-13 can be used for the research of cancer .

HY-177601

DGK-IN-11	DGK	Cancer
DGK-IN-11 (Compound 1) is a diacylglycerol kinase (DGK) inhibitor. DGK-IN-11 exhibits inhibitory activity against DGKα and DGKγ. DGK-IN-11 regulates intracellular diacylglycerol levels and enhances T cell activation, cytokine production, and proliferation. DGK-IN-11 can be used for the study of cancer .

HY-121638

CU-3	DGK Apoptosis Interleukin Related Caspase	Cancer
CU-3 is a DGKα inhibitor with an IC₅₀ of 0.6 μM. CU-3 competitively reduces DGKα’s affinity for ATP via binding to the enzyme’s catalytic region. CU-3 induces apoptosis in cancer cells. CU-3 promotes T-cell activation and enhances IL-2 production. CU-3 can be used for the research of hepatocellular carcinoma and cervical cancer .

HY-178062

DGKα-IN-10	DGK Interleukin Related	Cancer
DGKα-IN-10 is an orally active and potent DGKα inhibitor with an IC₅₀ of 0.27 nM. DGKα-IN-10 can induce IL-2 release and T cells proliferation. DGKα-IN-10 can be used for the research of cancer, such as colon cancer .

HY-156574

DGKζ-IN-4	DGK	Cancer
DGKζ-IN-4 is a DGK-zeta inhibitor. DGKζ-IN-4 can be used as an active component of pharmaceutical compositions. DGKζ-IN-4 is used to treat cancers associated with immune cell activation or cancers resistant to anti-PD-1 antibody/anti-PD-11 antibody research .

HY-158800

1-NBD-decanoyl-2-decanoyl-sn-glycerol	Biochemical Assay Reagents	Others
1-NBD-decanoyl-2-decanoyl-sn-glycerol is a diacylglycerol (DAG) derivative, which is labeled with a fluorescent group NBD. 1-NBD-decanoyl-2-decanoyl-sn-glycerol is the substrate for diacylglycerol kinase (DGK), and can be used for quantitative detection of the DGF enzyme kinetics in vitro, and the changes in DAG and PA during cell signaling .

HY-156572

DGKζ-IN-3	DGK	Cancer
DGKζ-IN-3 is a DGK-zeta-inhibitor. DGKζ-IN-3 is used in liquid and solid cancer and other diacylglycerol kinase zeta (DGK-ζ) regulation of diseases .

HY-122949

Momordicine I 2 Publications Verification	Apoptosis Autophagy DGK Mitochondrial Metabolism NO Synthase PI3K Akt Interleukin Related Src AMPK mTOR NF-κB c-Met/HGFR STAT Keap1-Nrf2 Reactive Oxygen Species (ROS) Oxidative Phosphorylation Endogenous Metabolite	Cardiovascular Disease Metabolic Disease Inflammation/Immunology Cancer
Momordicine I is a cucurbitane-type triterpenoids. Momordicine I suppresses glioma growth by promoting apoptosis and impairing mitochondrial oxidative phosphorylation. Momordicine I inhibits glycolysis, lipid metabolism, induces autophagy in HNC cells to suppress head and neck cancer growth. Momordicine I alleviates isoproterenol-induced cardiomyocyte hypertrophy through suppression of PLA2G6 and *DGK-ζ. Momordicine I exerts its cardiovascular benefits by upregulating nitric oxide, inhibiting the activity of angiotensin-converting enzyme (ACE), activating the PI3K/Akt* pathway, reducing oxidative stress and inflammation. Momordicine I inhibits AKT1, IL-6, and SRC, suggesting its potential application in type 2 diabetes .

HY-177602

DGK-IN-12	DGK	Cancer
DGK-IN-12 is a *DGK* inhibitor. DGK-IN-12 can be used for the research of cancer .

HY-178327

DGKα&ζ-IN-2	DGK Interleukin Related	Inflammation/Immunology Cancer
DGKα/ζ-IN-2 is a potent, orally active and selective dual DGKα/ζ inhibitor with IC₅₀ values of 23 nM (DGKα) and 1.2 nM (DGKζ). DGKα/ζ-IN-2 exhibits selectivity over other DGK isoforms, such as DGKβ and DGKγ. DGKα/ζ-IN-2 shows robust and dose-dependent immune activation in the presence of antigen presentation in an OT-1 murine model. DGKα/ζ-IN-2 can be used for antitumor immunity .

HY-175727

DGKα-IN-9	DGK	Cancer
DGKα-IN-9 is a diacylglycerol kinase alpha (DGKα) inhibitor. DGKα-IN-9 demonstrates a tumor growth inhibition in MC38 or or CT26 mouse tumor model. DGKα-IN-9 can be used for the study of cancer .

HY-160123

DGKζ-IN-5	DGK	Cancer
DGKζ-IN-5 is a DGKζ inhibitor (WO2023125681A1; compound A27a) .

HY-149666

BMS-496	DGK	Cancer
BMS-496 is adualDGKα/ζlipid kinase inhibitor, with theIC₅₀of 0.09 (DGKα) and 0.006 μM (DGKζ) .

HY-156578

DGKα-IN-8	DGK HIV	Infection Cancer
DGKα-IN-8 (Example 51) is a DGKα inhibitor (IC₅₀=22.491 nM; EC₅₀=0.256 nM). DGKα-IN-8 can be used to study cancer, including solid tumors, and viral infections, such as HIV or hepatitis B virus infection .

HY-159649A

(1R)-BMS-986408	DGK	Cancer
(1R)-BMS-986408 is an orally active dual DGK α/ζ inhibitor that restores T cell-mediated anti-tumor immunity by enhancing T cell signaling .

HY-148174

JNJ-3790339	DGK	Cancer
JNJ-3790339, a Ritanserin (HY-10791) analog, is a potent and selective *diacylglycerol kinase (DGKα)* inhibitor with an IC₅₀ of 9.6 μM. JNJ-3790339 has induction of toxicity in malignant cells, and improves ability to upregulate T cell activation .

HY-164905

DGK-IN-8	DGK	Cancer
DGK-IN-8 (Example 34) is a *DGK* inhibitor, with IC₅₀ of ≤ 20 nM for DGKα and ζ. DGK-IN-8 can be used for cancer research .

HY-156573

DGKα/ζ-IN-1	DGK	Cancer
DGKα/ζ-IN-1 (Compound II) is a DGK target inhibitor. DGKα/ζ-IN-1 can enhance the function of T cells, and has a synergistic effect with PD-1, which has therapeutic effects IN both immune and tumor .

HY-177107

DGK-IN-10	DGK	Cancer
DGK-IN-10 (example 61) is a *DGK* inhibitor with IC₅₀ values of ≤ 10 nM for both DGKα and DGKζ. DGK-IN-10 can be used for the research of diseases including cancer .

HY-170427

DGKζ-IN-10	DGK	Inflammation/Immunology
DGKζ-IN-10 (compound 349) is a DGKζ inhibitor, with an IC₅₀ ≤200 nM .

HY-170426

DGKζ-IN-9	DGK	Inflammation/Immunology
DGKζ-IN-9 (compound 73) is a DGKζ inhibitor, with an IC₅₀ ≤200 nM .

HY-156576

DGKα-IN-6	DGK	Cancer
DGKα-IN-6 is a DGKα inhibitor with the IC₅₀ of 1.377 nM, extracted from patent WO2022271650 (compound 143). DGKα-IN-6 has the potential for cancer study.

HY-156577

DGKα-IN-7	DGK	Cancer
DGKα-IN-7 is a DGKα inhibitor with the IC₅₀ of 6.225 nM, extracted from patent WO2022271684 (compound 100). DGKα-IN-7 has the potential for cancer study.

HY-156571

DGKα-IN-4	DGK	Cancer
DGKα-IN-4 (example 432) is a DGKα inhibitor with the IC₅₀ of 0.1 nM, extracted from patent WO2021105117. DGKα-IN-2 significantly enhances the anti-tumor effect of anti-PD-1 by increasing the proliferation and function of T cells. DGKα-IN-3 has the potential for cancer and immunology study.

HY-156570

DGKα-IN-3	DGK	Inflammation/Immunology Cancer
DGKα-IN-3 (example 25) is a DGKα inhibitor with the IC₅₀ of 283 nM, extracted from patent WO2021105115. DGKα-IN-2 significantly enhances the anti-tumor effect of anti-PD-1 by increasing the proliferation and function of T cells. DGKα-IN-2 has the potential for cancer and immunology study.

HY-RS03716

DGKB Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
DGKB Human Pre-designed siRNA Set A contains three designed siRNAs for DGKB gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

DGKB Human Pre-designed siRNA Set A DGKB Human Pre-designed siRNA Set A

HY-RS20713

Dgkh Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Dgkh Mouse Pre-designed siRNA Set A contains three designed siRNAs for Dgkh gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Dgkh Mouse Pre-designed siRNA Set A Dgkh Mouse Pre-designed siRNA Set A

HY-169318

DGKζ-IN-7	DGK Interleukin Related	Inflammation/Immunology Cancer
DGKζ-IN-7 (compound 97) is an oral active DGKζ inhibitor with the IC₅₀ of 33.4 nM. DGKζ-IN-6 inhibits the secretion of IL-2 and can be used for study of cancer and autoimmune diseases .

HY-169317

DGKζ-IN-6	DGK Interleukin Related	Inflammation/Immunology Cancer
DGKζ-IN-6 (compound 40) is an oral active DGKζ inhibitor with the IC₅₀ of 45.5 nM. DGKζ-IN-6 inhibits the secretion of IL-2 and can be used for study of cancer and autoimmune diseases .

HY-RS03718

DGKE Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
DGKE Human Pre-designed siRNA Set A contains three designed siRNAs for DGKE gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

DGKE Human Pre-designed siRNA Set A DGKE Human Pre-designed siRNA Set A

HY-RS03725

DGUOK Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
DGUOK Human Pre-designed siRNA Set A contains three designed siRNAs for DGUOK gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

DGUOK Human Pre-designed siRNA Set A DGUOK Human Pre-designed siRNA Set A

HY-156575S

DGKα-IN-5	Isotope-Labeled Compounds	Others
DGKα-IN-5 is a deuterium labeled compound.

HY-156567

AMB639752	DGK	Metabolic Disease
AMB639752 is a potent DGKα inhibitor. AMB639752 restores restimulation induced cell death (RICD) in SAP deficient lymphocytes by inhibiting DGKα in intact cells. AMB639752 can be used for X-linked lymphoproliferative disease 1(XLP-1) research .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-122949

Momordicine I 2 Publications Verification	Triterpenes Terpenoids Cucurbitaceae Plants Momordica charantia Linn. Source Classification	Apoptosis Autophagy DGK Mitochondrial Metabolism NO Synthase PI3K Akt Interleukin Related Src AMPK mTOR NF-κB c-Met/HGFR STAT Keap1-Nrf2 Reactive Oxygen Species (ROS) Oxidative Phosphorylation Endogenous Metabolite
Momordicine I is a cucurbitane-type triterpenoids. Momordicine I suppresses glioma growth by promoting apoptosis and impairing mitochondrial oxidative phosphorylation. Momordicine I inhibits glycolysis, lipid metabolism, induces autophagy in HNC cells to suppress head and neck cancer growth. Momordicine I alleviates isoproterenol-induced cardiomyocyte hypertrophy through suppression of PLA2G6 and *DGK-ζ. Momordicine I exerts its cardiovascular benefits by upregulating nitric oxide, inhibiting the activity of angiotensin-converting enzyme (ACE), activating the PI3K/Akt* pathway, reducing oxidative stress and inflammation. Momordicine I inhibits AKT1, IL-6, and SRC, suggesting its potential application in type 2 diabetes .

Species:	Human (3)
Tag:	His (3) Strep (1) Myc (1) GST (1)
Source:	sf9 insect cells (2) Sf9 insect cells (1)

Cat. No.	Compare	Product Name	Species	Source	Image

HY-P705807

	DGKG Protein, Human (sf9, His-StrepII) Diacylglycerol kinase gamma; dgk-gamma; DAGK3	Human	sf9 insect cells

HY-P702617

	DGKA Protein, Human (sf9, His, Myc) 80 kDa diacylGlycerol kinase; DAG kinase alpha; DAGK; DAGK1; dgk alpha; dgk-alpha; dgkA; dgkA_HUMAN; DiacylGlycerol kinase alpha; DiacylGlycerol kinase; alpha 80kDa; Diglyceride kinase alpha; MGC12821; MGC42356; OTTHUMP00000242836; OTTHUMP00000242955; OTTHUMP00000244046	Human	Sf9 insect cells
	The DGKA protein converts diacylglycerol (DAG) into phosphatidic acid (PA), regulates its levels and serves as a central switch between signaling pathways. DGKA Protein, Human (sf9, His, Myc) is the recombinant human-derived DGKA, expressed by Sf9 insect cells, with C-Myc, N-10His labeled tag. The total length of DGKA Protein, Human (sf9, His, Myc) is 735 a.a.*.

HY-P705806

	DGKA Protein, Human (sf9, His-GST) 80 kDa diacylGlycerol kinase; DAG kinase alpha; DAGK; DAGK1; dgk alpha; dgk-alpha; dgkA; dgkA_HUMAN; DiacylGlycerol kinase alpha; DiacylGlycerol kinase; alpha 80kDa; Diglyceride kinase alpha; MGC12821; MGC42356; OTTHUMP00000242836; OTTHUMP00000242955; OTTHUMP00000244046	Human	sf9 insect cells

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-156575S

DGKα-IN-5
DGKα-IN-5 is a deuterium labeled compound.

Host:	Rabbit (5)
Reactivity:	Human (5) Mouse (1) Rat (3)
Application:	IHC-P (5) ICC/IF (1) IP (2) WB (3) FC (1)
Isotype:	IgG (5)
Conjugation:	Non-conjugated (5)
Clonality:	Monoclonal (3) Recombinant (2)
Modification:	Unmodified (3)

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P83116

	DGKA Antibody (YA2861) DAGK; DAGK1; dgk-alpha	WB, IHC-P, IP	Human
	DGKA Antibody (YA2861) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to DGKA.

HY-P81477

	DGKZ Antibody (YA1222) DAGK5; DAGK6; dgk-ZETA; hdgkzeta	IHC-P	Human, Rat
	DGKZ Antibody (YA1222) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to DGKZ.

HY-P83116A

	DGKA Antibody (YA2861)(PBS only) DAGK; DAGK1; dgk-alpha	WB, IHC-P, IP	Human
	DGKA Antibody (YA2861) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to DGKA.

HY-P810494

	DGKZ Antibody (YA9787) DAGK5, DAGK6, dgk-ZETA, hdgkzeta, dgkZ	WB, IHC-P, ICC/IF, FC	Human, Mouse, Rat
	DGKZ Antibody (YA9787) is a Rabbit-derived and non-conjugated IgG Monoclonal antibody, targeting to DGKZ.

HY-P81477A

	DGKZ Antibody (YA1222)(PBS only) DAGK5; DAGK6; dgk-ZETA; hdgkzeta	IHC-P	Human, Rat
	DGKZ Antibody (YA1222) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to DGKZ.